DanCann Pharma A/S: Extraordinary exercise period for warrants commences today as a result application for delisting

DanCann Pharma announced its general meeting approved a voluntary delisting application from Spotlight Stock Market to be submitted on 7 January 2026, with last trading day subject to approval on 22 January 2026. The company has opened an extraordinary warrant exercise period effective today through 12 January 2026 for 1,224,993 outstanding warrants (each exercisable into one DKK 1 share at DKK 2.60), which if fully exercised would increase share capital by nominally DKK 1,224,993 and may cause dilution while removing public market liquidity.

Analysis

Market structure: The delisting notice creates a near-term liquidity squeeze and potential supply overhang — 1,224,993 warrants exercisable at DKK 2.60 (gross proceeds DKK ~3.185m) will either convert into new shares or remain unexercised, concentrating upside for warrant holders and pressuring free-float ahead of last trade on 22 Jan 2026. Warrant holders (top holder JEQ Capital 197,452 ~16% of warrants) directly benefit; minority public shareholders and market makers lose pricing transparency and post-delist liquidity.

Risk assessment: Tail risks include a failed delisting application, legal challenges from minority holders, mass non-payment of subscription proceeds, or sudden regulatory action on cannabinoid assets — any of which could force insolvency or a distressed private recapitalization. Time windows matter: immediate (today–12 Jan 2026) is the exercise window; short-term (12–22 Jan) is trading/flow risk; long-term (post-delist) is illiquidity and financing risk.

Trade implications: Best actionable plays are event-driven and conditional: short-biased on expected pre-delist selling and thin liquidity, or a conditional long if >50% warrants are exercised (cash ≥DKK1.59m) signalling committed investor bridge financing. Options/structured hedges (puts or collars) around the 22 Jan delisting date capture skew; avoid leverage into the delist event given execution risk.

Contrarian angles: Consensus treats delisting as negative — but if exercise >75% (≈918k warrants) the company would receive ≈DKK2.39m, materially lowering immediate refinancing risk and creating a mispriced post-exercise stub if market underestimates cash impact. Historical small-cap delistings often reprice higher privately when key insiders fund operations; monitor exercise disclosure as the primary reverse catalyst.

Key Decisions for Investors

• Initiate a tactical short in DanCann Pharma (SS: DANCAN) size 1–2% NAV via borrow/CFD before 12 Jan 2026 to capture expected pre-delist selling and illiquidity; target 30–50% downside, place stop-loss at +20% of entry, time horizon: close by 22 Jan 2026 or on exercise disclosure.
• Prepare a conditional long: deploy up to 1–2% NAV long DANCAN only if company discloses warrant exercise >=50% (≥612,497 warrants exercised => cash-in ≥DKK1.59m) within 3 trading days of 12 Jan 2026; take profit or re-evaluate at 3 months post-delist.
• Buy downside protection: purchase puts or set up a collar on DANCAN with ~20% OTM protection expiring 30 days after last trading day (around 22 Feb 2026) sized to cover existing exposure or short position; if exchange-listed options absent, use Nordic single-stock put structures or OTC options.
• Reduce active exposure to Spotlight-listed small-cap biotech names by 1–3% NAV through Jan–Mar 2026 to lower event-driven delisting and liquidity risk concentration; redeploy into liquid biotech ETFs (e.g., IBB) or large-cap pharma for similar thematic exposure with lower microcap tail risk.